James E Tooley1, Kevan C Herold. 1. Department of Immunobiology and Internal Medicine, Yale University, New Haven, Connecticut, USA.
Abstract
PURPOSE OF REVIEW: Biomarkers of type 1 diabetes (T1D) are important for assessing risk of developing disease, monitoring disease progression, and determining responses to clinical treatments. Here we review recent advances in the development of biomarkers of T1D with a focus on their utility in clinical trials. RECENT FINDINGS: Measurements of autoantibodies and metabolic outcomes have been the foundation of monitoring T1D for the past 20 years. Recent advancements have led to improvements in T-cell-specific assays that have been used in large-scale clinical trials to measure antigen-specific T cell responses. Additionally, new tools are being developed for the measurement of β cell mass and death that will allow for more direct measurement of disease activity. Lastly, recent studies have used both immunologic and nonimmunologic biomarkers to identify responders to treatments in clinical trials. SUMMARY: Use of biomarkers in the study of T1D has largely not changed over the past 20 years; however, recent advancements in the field are establishing new techniques that allow for more precise monitoring of disease progression. These new tools will ultimately lead to an improvement in understanding of disease and will be utilized in clinical trials.
PURPOSE OF REVIEW: Biomarkers of type 1 diabetes (T1D) are important for assessing risk of developing disease, monitoring disease progression, and determining responses to clinical treatments. Here we review recent advances in the development of biomarkers of T1D with a focus on their utility in clinical trials. RECENT FINDINGS: Measurements of autoantibodies and metabolic outcomes have been the foundation of monitoring T1D for the past 20 years. Recent advancements have led to improvements in T-cell-specific assays that have been used in large-scale clinical trials to measure antigen-specific T cell responses. Additionally, new tools are being developed for the measurement of β cell mass and death that will allow for more direct measurement of disease activity. Lastly, recent studies have used both immunologic and nonimmunologic biomarkers to identify responders to treatments in clinical trials. SUMMARY: Use of biomarkers in the study of T1D has largely not changed over the past 20 years; however, recent advancements in the field are establishing new techniques that allow for more precise monitoring of disease progression. These new tools will ultimately lead to an improvement in understanding of disease and will be utilized in clinical trials.
Authors: Eitan M Akirav; Jasmin Lebastchi; Eva M Galvan; Octavian Henegariu; Michael Akirav; Vitaly Ablamunits; Paul M Lizardi; Kevan C Herold Journal: Proc Natl Acad Sci U S A Date: 2011-11-09 Impact factor: 11.205
Authors: David Hadley; Roy K Cheung; Dorothy J Becker; Rose Girgis; Jerry P Palmer; David Cuthbertson; Jeffrey P Krischer; Hans-Michael Dosch Journal: Clin Vaccine Immunol Date: 2013-12-11
Authors: K C Herold; S E Gitelman; S M Willi; P A Gottlieb; F Waldron-Lynch; L Devine; J Sherr; S M Rosenthal; S Adi; M Y Jalaludin; A W Michels; J Dziura; J A Bluestone Journal: Diabetologia Date: 2012-10-21 Impact factor: 10.122
Authors: Kevan C Herold; Stephen E Gitelman; Mario R Ehlers; Peter A Gottlieb; Carla J Greenbaum; William Hagopian; Karen D Boyle; Lynette Keyes-Elstein; Sudeepta Aggarwal; Deborah Phippard; Peter H Sayre; James McNamara; Jeffrey A Bluestone Journal: Diabetes Date: 2013-07-08 Impact factor: 9.461
Authors: Frank Waldron-Lynch; Octavian Henegariu; Songyan Deng; Paula Preston-Hurlburt; James Tooley; Richard Flavell; Kevan C Herold Journal: Sci Transl Med Date: 2012-01-25 Impact factor: 17.956
Authors: Wendy W J Unger; Todd Pearson; Joana R F Abreu; Sandra Laban; Arno R van der Slik; Sacha Mulder-van der Kracht; Michel G D Kester; Dave V Serreze; Leonard D Shultz; Marieke Griffioen; Jan Wouter Drijfhout; Dale L Greiner; Bart O Roep Journal: PLoS One Date: 2012-11-14 Impact factor: 3.240
Authors: Jasmin Lebastchi; Songyan Deng; Amir H Lebastchi; Isabel Beshar; Stephen Gitelman; Steven Willi; Peter Gottlieb; Eitan M Akirav; Jeffrey A Bluestone; Kevan C Herold Journal: Diabetes Date: 2013-02-19 Impact factor: 9.461
Authors: Stina Axelsson; Mikael Chéramy; Linda Akerman; Mikael Pihl; Johnny Ludvigsson; Rosaura Casas Journal: Diabetes Care Date: 2013-07-17 Impact factor: 19.112
Authors: James C Needell; Charles A Dinarello; Diana Ir; Charles E Robertson; Sarah M Ryan; Miranda E Kroehl; Daniel N Frank; Danny Zipris Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240
Authors: Steven E Kahn; Yi-Chun Chen; Nathalie Esser; Austin J Taylor; Daniël H van Raalte; Sakeneh Zraika; C Bruce Verchere Journal: Endocr Rev Date: 2021-09-28 Impact factor: 25.261
Authors: Tanya C Burch; Margaret A Morris; Martha Campbell-Thompson; Alberto Pugliese; Jerry L Nadler; Julius O Nyalwidhe Journal: PLoS One Date: 2015-08-24 Impact factor: 3.240